Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4924-4930

  Denmeade, Samuel R ^a,b   Lou, Wei ^a   Lövgren, Janita ^c   Malm, Johan ^d   Lilja, Hans ^d   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TURKU   (Finland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; XENOGRAFT;

ALPHA 1-ANTICHYMOTRYPSIN; ANIMALS; ENZYME INHIBITORS; EXTRACELLULAR SPACE; GONADAL STEROID HORMONES; HUMANS; HYDROLYSIS; KINETICS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE MAPPING; PRECIPITIN TESTS; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEMINAL VESICLE SECRETORY PROTEINS; SUBSTRATE SPECIFICITY; THAPSIGARGIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030728733     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (Phila.), 71: 1098-1109, 1993.
2. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 65: 5-27, 1996.
3. Schultz, H., Isaacs, J. T., and Coffey, D. S. A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. Prog. Clin. Biol. Res., 243A: 1-19, 1987.
4. Berges, R. S., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implication of cell kinetic changes during the progression of human prostatie cancer. Clin. Cancer Res., 1: 473-480, 1995.
5. Isaacs, J. T., and Lundmo, P. Chemotherapeutic induction of programmed cell death in nonproliferating prostate cancer cells. Proc. Am. Assoc. Cancer Res., 33: 588-589, 1992.
6. Furuya, Y., Lundmo, P., Short, A. D., Gill, D. L., and Isaacs, J. T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 54: 6167-6175, 1994.
7. Furuya, Y., and Isaacs, J. T. Proliferation dependent versus independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate, 25: 301-309, 1994.
8. Lin, X. S., Denmeade, S. R., Cisek, L., and Isaacs, J. The mechanism and role of growth arrest in programmed (apoptotic) death of prostate cancer cells induced by thapsigargin. Prostate, in press, 1997.
9. Denmeade, S. R., and Isaacs, I. T. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv. Pharmacol., 35: 281-306, 1996.
10. Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol., 17: 159-163, 1979.
11. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest., 76: 1899-1903, 1985.
12. Watt, K. W. K., Lee. P-J., M'Timkulu, T., Chan, W-P., and Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA, 83: 3166-3170, 1986.
13. Yu, H., Diamandis, E. P., Levesque, M., Giai, M., Roagna, R., Ponzone, R., Sismondi, P., Monne, M., and Croce, C. M., Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res. Treat., 40: 171-178, 1996.
14. Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Levesque, M. A., and Diamandis, E. P. Prostate-specific antigen in serum of women with breast cancer. Br. J. Cancer. 72: 728-731, 1995.
15. Christensson, A., Laurell, C-B., and Lilja, Hans. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur. J. Biochem., 194: 755-765, 1990.
16. Lilja, H., Abrahamsson, P-A., and Lundwall, A. Semenogelin, the predominant protein in human semen. J. Biol. Chem., 264: 1894-1900, 1989.
17. Akiyama, K., Nakamura, T., Iwanaga, S., and Hara, H. The chymotrypsin-like activity of human prostate-specific antigen γ-seminoprotein. FEBS Lett., 225: 1894-1900, 1987.
18. Lilja, H., Oldbring, J., Rannevik, G., and Laurell, C-B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefication of human semen. J. Clin. Invest., 80: 281-285, 1987.
19. Malm, J., Hellman, J., and Lilja, H. Mapping of the unique enzyme characteristics of PSA. J. Urol., 157 (Suppl.): 345, 1997.
20. Kurkela, R., Herrala, A., Henttu, P., Nal, H., and Vihko, P. Expression of active, secreted human prostate-specific antigen by recombinant baculovirus-infected insect cells on a pilot scale. Biotechnology, 13: 1230-1234, 1995.
21. Lovgren, J., Piironen, T., Overmo, C., Dowell, B., Karp, M., Pettersson, K., Lilja, H., Lundwall, A. Production of recombinant PSA and hk2 and analysis of their immunologic cross-reactivity. Biochem. Biophys. Res. Commun., 213: 888-895, 1995.
22. 1-anti-chymotrypsin complex. Clin. Chem., 41: 1480-1488, 1995.
23. 1-anti-chymotrypsin. Clin. Chem., 37: 1618-1625, 1991.
24. Hoehn, W., Schroeder, F. H., Riemann, J. F., Joebsis, A. C., and Hermanek, P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate, 1: 94-104, 1980.
25. Csapo, Z., Brand, K., Wlather, R., and Fokas, K. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J. Urol., 140: 1032-1038, 1988.
26. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
27. Webber, M. M., Waghray, A., and Bello, D. Prostate specific antigen, a serine protease. facilitates human prostatic cancer cell invasion. Clin. Cancer Res., 1: 1089-1094, 1995.
28. Cohen, P., Graves, H. C. B., Peehl, D. M., Kamarei, M., Giudice, L. C., and Rosenfeld, R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab., 75: 1046-1053, 1992.
29. Yoshida, E., Ohmura, S., Sugiki, M., Maruyama, M., and Mihara, H. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int. J. Cancer, 63: 863-865, 1995.
30. Iwamura, M., Hellman, J., Cockett, A. T., Lilja, H., and Gershagen, S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology, 48: 317-325, 1996.
31. Sloane, B. F., Moin, K., Krepela, E., and Rozhin, J. Cathepsin B and its endogenous inhibitors: role in tumor malignancy. Cancer Metast. Rev., 9: 333-352, 1990.
32. Sloane, B. F., Rozhin, J., Taylor, H., Crissman, J. D., and Honn, K. V. Cathepsin B: association with plasma membrane in metastatic tumors. Proc. Natl. Acad. Sci. USA, 83: 2483-2487, 1986.
33. Krepela, E., Bartek, J., Skalova, D., Vicar, J., Rasnick, D., Taylor-Papadimitriou, J., and Hallowes, R. C. Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells. J. Cell Sci., 87: 145-154, 1987.
34. Sinha, A. A., Wilson, M. J., Gleason, D. F., Reddy, P. K., Sameni, M., and Sloane, B. F. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate, 26: 171-178, 1995.
35. Sinha, A. A., Gleason, D. F., Staley, N. A., Wilson, M. J., Sameni, M., and Sloane, B. F. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat. Rec., 241: 353-362, 1995.
36. Lundwall, A., and Lilja, H. Molecular cloning of human prostate-specific antigen cDNA. FEBS Lett., 214: 317-322, 1987.
37. Takayama, T. K., Fujikawa, K., Davie, E. W., and Lange, P. H. Comparisons of recombinant with seminal plasma-purified human prostate specific antigen. Proc. Am. Urol. Assoc., 155: 338A, 1996.